The meeting will get started in
Days
Hours
Minutes
Seconds
ID | Title | Type of abstract | Burton | Deik | Duda | Sarva | Yacoubian | Mean | Decision |
---|---|---|---|---|---|---|---|---|---|
422 | A Telehealth Psychotherapy Hub Improves Access to Mental Health Care for Rural Veterans with Parkinson’s Disease | Regular Abstract | 1 | 2 | 2 | 2 | 1.75 | Accept | |
421 | WATCH-PD: Remotely monitored sensor-based digital biomarkers of early PD status | Late Breaking Research Abstract | 2 | 2 | 1 | 1 | 1.5 | Accept | |
420 | Hemifacial spasm associated with a caffeine-based weight loss supplement: a case report and review of the literature | Regular Abstract | 0 | 0 | 1 | 0.333333333 | Reject | ||
417 | Human Tissue Engineered Nigrostriatal Pathways Restore Axon Tracts to Improve Striatal Dopamine Levels in a Rat Model of Parkinson’s Disease | Late Breaking Research Abstract | 2 | 3 | 3 | 2.666666667 | Accept | ||
416 | Efficacy of Deep Brain Stimulation on Perception of Pain Intensity | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
415 | Does total dietary protein intake affect motor and cognitive function in Parkinson’s Disease? | Regular Abstract | 1 | 2 | 1 | 1 | 1.25 | Accept | |
414 | Evaluating the Implementation and Impact of a Neurology Research Contact Registry on Recruitment for Parkinson’s disease Research Studies | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
412 | Imaging caffeine-mediated blockade of striatal adenosine A2A receptors in LRRK2 G2019S carriers | Regular Abstract | 1 | 2 | 1 | 1 | 1.25 | Accept | |
411 | Effect of istradefylline dosage on unified Parkinsons’ disease rating scale (UPDRS) III-ON scores: Results from four randomized clinical trials | Regular Abstract | 1 | 2 | 1 | 1 | 1.25 | Accept | |
410 | Optimizing patient-centric clinical outcome assessments for use in Parkinson’s disease clinical trials: Critical Path for Parkinson’s multistakeholder initiative | Regular Abstract | 0 | 1 | 0.5 | Accept | |||
409 | Progression of gait disturbances in people with Parkinson’s disease and REM sleep without atonia | Regular Abstract | 1 | 2 | 2 | 1 | 1.5 | Accept | |
408 | Caffeine Attenuates Lipopolysaccharide-induced Astrocytosis in LRRK2 G2019S Knock-in Mice. | Regular Abstract | 1 | 1 | 2 | 2 | 1.5 | Accept | |
404 | Vitamin B12 inhibits LRRK2 kinase activity in neuronal cells overexpressing the G2019S variant pathogenic for Parkinson’s disease | Regular Abstract | 1 | 2 | 2 | 1 | 1.5 | Accept | |
403 | Expanding clinical genetic testing and counseling to people with Parkinson’s disease: PD GENEration study update | Late Breaking Research Abstract | 1 | 2 | 1 | 1.333333333 | Accept | ||
401 | Investigating Conventional and Advanced Diffusion-MRI Measures to Understand White Matter Pathology in Parkinson’s disease Patients with Cognitive Impairment | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
400 | An agnostic pesticide-wide association approach to investigating agricultural pesticide use and Parkinson’s disease | Regular Abstract | 1 | 2 | 2 | 3 | 2 | Accept | |
399 | Development of a Novel Questionnaire on Women’s Health to Understand Its Role in Parkinson’s Disease Development and Progression | Regular Abstract | 1 | 2 | 2 | 1 | 1.5 | Accept | |
398 | Preliminary results from real-world data collection in RAD-PD | Regular Abstract | 1 | 2 | 2 | 1 | 1.5 | Accept | |
395 | Association between clinical motor symptoms and peripheral inflammatory cytokines after group therapeutic singing in persons with Parkinson’s disease | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
394 | Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson disease | Regular Abstract | 1 | 0 | 1 | 0 | 0.5 | Accept | |
393 | Optimization of recruitment for movement disorders clinical trials in a pandemic: a single center experience | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
392 | An experimental paradigm for testing effect of alternating-frequency Deep Brain Stimulation on gait, in Parkinson Disease | Regular Abstract | 1 | 2 | 1 | 1.333333333 | Accept | ||
390 | Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD) | Regular Abstract | 1 | 1 | 1 | 1 | 1 | Accept | |
389 | A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early-stage Parkinson’s disease) | Regular Abstract | 1 | 3 | 2 | 3 | 2.25 | ||
388 | Imaging regional histone deacetylase expression in dementia with Lewy bodies with [11C]Martinostat PET | Regular Abstract | 1 | 2 | 2 | 1 | 1.5 | ||
ID | Title | Type of abstract | Burton | Deik | Duda | Sarva | Yacoubian | Mean | Decision |